Partha Pratim Dutta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Partha Pratim Dutta has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Lunasmrita Saikia
Faculty of Pharmaceutical Science, Assam Down Town University, Guwahati, India
14 shared publicationsSaikat Sen
Faculty of Pharmaceutical Science Assam Down Town University Guwahati Assam India
10 shared publicationsDouglas Law
Faculty of Health and Life Sciences, INTI International University, Nilai, Malaysia
5 shared publicationsNarayan Chandra Talukdar
5 shared publicationsDhrubajyoti Gogoi
Programme of Biotechnology, Faculty of Science, Assam Down Town University
4 shared publicationsJyotirmoy Bhattacharyya
4 shared publications
Latest Publications
- 3 November 2026
- Published byĀ Springer NatureĀ inĀ Current Bladder Dysfunction Reports
- Vol.Ā 21 Ā (1) , 44
Systematic Review and Meta-analysis of Randomised Clinical Trials Investigating Non-antibiotic Strategies for the Management of Urinary Tract Infections
- 3 November 2026
- Published byĀ Springer NatureĀ inĀ Current Bladder Dysfunction Reports
- Vol.Ā 21 Ā (1) , 44
Systematic Review and Meta-analysis of Randomised Clinical Trials Investigating Non-antibiotic Strategies for the Management of Urinary Tract Infections
- 31 July 2026
- Published byĀ WileyĀ inĀ Chemistry & Biodiversity
- Vol.Ā 23 Ā (8) , e71521
A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates HighāFat HighāFructose Diet/StreptozotocināInduced Diabetes via GLUTā4 Modulation
Euphorbia antiquorum L. (Euphorbiaceae), a traditionally used Asian medicinal plant, was systematically evaluated for its antidiabetic efficacy through a bioactivityāguided approach integrating in vitro, in vivo, and in silico studies. Among the four solvent fractions of the ethanolic stem extract, the ethyl acetate fraction exhibited the highest antioxidant and glucose utilization activity. Column chromatography of the ethyl acetate fraction yielded several subfractions, among which Fraction 2 (CEA2) showed strong antioxidant activity and significantly enhanced glucose utilization and GLUT4 translocation (p < 0.01). In a 63āday highāfat highāfructose diet and lowādose streptozotocināinduced diabetic rat model, CEA2 (200 and 400 mg/kg) markedly reduced fasting blood glucose, improved body weight, restored biochemical parameters, and decreased TNFāα and ILā6 levels, while also improving pancreatic and hepatic histopathology. Western blotting confirmed significant upregulation of plasma membrane GLUT4 (p < 0.01). LCāMS profiling identified major compounds, including 3āOātransāpācoumaroyltormentic acid and geranyl acetoacetate, which demonstrated strong binding to IRSā1 and AktāPKB in docking and molecular dynamics analyses, key regulators of GLUT4 vesicle mobilization. This study provides one of the first comprehensive validations establishing CEA2 as a potent modulator of insulin signaling and GLUT4 mobilization, supporting E. antiquorum as a promising phytopharmaceutical candidate for type 2 diabetes management.
- 31 July 2026
- Published byĀ WileyĀ inĀ Chemistry & Biodiversity
- Vol.Ā 23 Ā (8) , e71521
A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates HighāFat HighāFructose Diet/StreptozotocināInduced Diabetes via GLUTā4 Modulation
Euphorbia antiquorum L. (Euphorbiaceae), a traditionally used Asian medicinal plant, was systematically evaluated for its antidiabetic efficacy through a bioactivityāguided approach integrating in vitro, in vivo, and in silico studies. Among the four solvent fractions of the ethanolic stem extract, the ethyl acetate fraction exhibited the highest antioxidant and glucose utilization activity. Column chromatography of the ethyl acetate fraction yielded several subfractions, among which Fraction 2 (CEA2) showed strong antioxidant activity and significantly enhanced glucose utilization and GLUT4 translocation (p < 0.01). In a 63āday highāfat highāfructose diet and lowādose streptozotocināinduced diabetic rat model, CEA2 (200 and 400 mg/kg) markedly reduced fasting blood glucose, improved body weight, restored biochemical parameters, and decreased TNFāα and ILā6 levels, while also improving pancreatic and hepatic histopathology. Western blotting confirmed significant upregulation of plasma membrane GLUT4 (p < 0.01). LCāMS profiling identified major compounds, including 3āOātransāpācoumaroyltormentic acid and geranyl acetoacetate, which demonstrated strong binding to IRSā1 and AktāPKB in docking and molecular dynamics analyses, key regulators of GLUT4 vesicle mobilization. This study provides one of the first comprehensive validations establishing CEA2 as a potent modulator of insulin signaling and GLUT4 mobilization, supporting E. antiquorum as a promising phytopharmaceutical candidate for type 2 diabetes management.
- 10 June 2026
- Published byĀ Taylor & FrancisĀ inĀ Natural Product Research
- p. 1-6
Integrative experimental and computational analysis of a bioactivity guided fraction of Potentilla fulgens targeting oxidative stress and inflammatory pathways in diabetic neuropathy
1. Diabetes mellitus (DM) is one of the key triggers of illness and death worldwide. It affected 537 million people in 2021 and is expected to affect 783 million by 2045. Over 90% of occurrences ar...
- 10 June 2026
- Published byĀ Taylor & FrancisĀ inĀ Natural Product Research
- p. 1-6
Integrative experimental and computational analysis of a bioactivity guided fraction of Potentilla fulgens targeting oxidative stress and inflammatory pathways in diabetic neuropathy
1. Diabetes mellitus (DM) is one of the key triggers of illness and death worldwide. It affected 537 million people in 2021 and is expected to affect 783 million by 2045. Over 90% of occurrences ar...
- 25 May 2026
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 481 Ā (7) , 2997-3016
Deciphering the anticancer potential of an entomopathogenic fungus, Cordyceps militaris in Daltonās Lymphoma transplanted murine model: a multidimensional approach involving computational methods and in vivo validation
Cordyceps militaris, a medicinal mushroom in traditional Chinese medicine, emerged as a promising source of bioactive compounds, exhibiting potent antioxidant, anti-inflammatory, anticancer, antiviral and immunomodulatory properties. Despite documenting in vitro cytotoxicity against various cancer cell lines, in vivo efficacy against Dalton's Lymphoma (DL) remains underexplored. This study investigates the anticancer efficacy of methanolic Cordyceps militaris extract (CME) against DL-bearing mice, and validate its molecular mechanism via in-silico approaches. DL-bearing Swiss albino mice treated with varying doses of CME showed significant tumor volume reduction and improved survival rates and cytotoxicity. Apoptosis induction, cell cycle progression, mitochondrial membrane potential and DNA fragmentation were analyzed using AO/EB dual staining, flow cytometry, Rhodamine-123 and comet assay, respectively. Molecular docking and dynamics simulations were performed to validate the interactions of CME's potent bioactive compound, cordycepin with anti-apoptotic target proteins, BCL-2, BCL-xL and BFL-1. CME treatment (24-96 h) led to dose- and time-dependent apoptosis supported by scanning electron microscopy, G2/M phase arrest, mitochondrial membrane depolarization and substantial DNA damage characterized by increased tail length, % tail DNA and olive tail moment in comet assay. Docking and MD simulations established strong and stable binding affinity of cordycepin to BFL-1 throughout 100ns simulation time, corroborating in vivo apoptotic outcomes. CME induces mitochondria-mediated apoptosis, DNA damage and cell cycle arrest in DL cells. This highlights the potential of C. militaris as a natural anticancer drug against lymphoma, thereby warranting further clinical validation for phytotherapeutic applications.
- 25 May 2026
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 481 Ā (7) , 2997-3016
Deciphering the anticancer potential of an entomopathogenic fungus, Cordyceps militaris in Daltonās Lymphoma transplanted murine model: a multidimensional approach involving computational methods and in vivo validation
Cordyceps militaris, a medicinal mushroom in traditional Chinese medicine, emerged as a promising source of bioactive compounds, exhibiting potent antioxidant, anti-inflammatory, anticancer, antiviral and immunomodulatory properties. Despite documenting in vitro cytotoxicity against various cancer cell lines, in vivo efficacy against Dalton's Lymphoma (DL) remains underexplored. This study investigates the anticancer efficacy of methanolic Cordyceps militaris extract (CME) against DL-bearing mice, and validate its molecular mechanism via in-silico approaches. DL-bearing Swiss albino mice treated with varying doses of CME showed significant tumor volume reduction and improved survival rates and cytotoxicity. Apoptosis induction, cell cycle progression, mitochondrial membrane potential and DNA fragmentation were analyzed using AO/EB dual staining, flow cytometry, Rhodamine-123 and comet assay, respectively. Molecular docking and dynamics simulations were performed to validate the interactions of CME's potent bioactive compound, cordycepin with anti-apoptotic target proteins, BCL-2, BCL-xL and BFL-1. CME treatment (24-96 h) led to dose- and time-dependent apoptosis supported by scanning electron microscopy, G2/M phase arrest, mitochondrial membrane depolarization and substantial DNA damage characterized by increased tail length, % tail DNA and olive tail moment in comet assay. Docking and MD simulations established strong and stable binding affinity of cordycepin to BFL-1 throughout 100ns simulation time, corroborating in vivo apoptotic outcomes. CME induces mitochondria-mediated apoptosis, DNA damage and cell cycle arrest in DL cells. This highlights the potential of C. militaris as a natural anticancer drug against lymphoma, thereby warranting further clinical validation for phytotherapeutic applications.
- 21 May 2026
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 481 Ā (6) , 2357-2379
Flavonoids as functional food-derived modulators of the gut microbiota-NF-ĪŗB axis in metabolic dysfunction-associated steatotic liver disease
Metabolically Dysfunctional-Associated Steatotic Liver Disease (MASLD) is increasingly recognised as a gut-liver axis disorder driven by sustained activation of pro-inflammatory signalling networks, particularly the NF-ĪŗB pathway. Flavonoids, a diverse class of dietary polyphenols, have emerged as promising modulators of NF-ĪŗB-mediated gut-liver crosstalk due to their capacity to restore intestinal homeostasis and suppress hepatic inflammation. This review synthesises recent preclinical evidence identifying NF-ĪŗB as a central mechanistic target underlying flavonoid actions in MASLD. A structured literature search was conducted in PubMed, Scopus, Web of Science, and ScienceDirect to identify studies published between 2020 and February 2026. Accumulating evidence indicates that flavonoids remodel the gut microbiota toward beneficial taxa. Several flavonoids also modulate upstream regulators, thereby converging on NF-ĪŗB to mitigate MASLD. To improve translational interpretation, animal experimental doses were contextualised using established human-equivalent dose conversion methods, alongside reported dietary sources and estimated achievable intake levels. Although the present work highlights the considerable potential of flavonoids as functional food-derived modulators of the gut microbiota NF-ĪŗB axis in MASLD, their clinical translation remains constrained by limited bioavailability and heterogeneity across experimental models, highlighting the need for standardised dosing strategies, integrated host microbiota analyses, and well-designed human studies to substantiate clinical applicability.
- 21 May 2026
- Published byĀ Springer NatureĀ inĀ Molecular and Cellular Biochemistry
- Vol.Ā 481 Ā (6) , 2357-2379
Flavonoids as functional food-derived modulators of the gut microbiota-NF-ĪŗB axis in metabolic dysfunction-associated steatotic liver disease
Metabolically Dysfunctional-Associated Steatotic Liver Disease (MASLD) is increasingly recognised as a gut-liver axis disorder driven by sustained activation of pro-inflammatory signalling networks, particularly the NF-ĪŗB pathway. Flavonoids, a diverse class of dietary polyphenols, have emerged as promising modulators of NF-ĪŗB-mediated gut-liver crosstalk due to their capacity to restore intestinal homeostasis and suppress hepatic inflammation. This review synthesises recent preclinical evidence identifying NF-ĪŗB as a central mechanistic target underlying flavonoid actions in MASLD. A structured literature search was conducted in PubMed, Scopus, Web of Science, and ScienceDirect to identify studies published between 2020 and February 2026. Accumulating evidence indicates that flavonoids remodel the gut microbiota toward beneficial taxa. Several flavonoids also modulate upstream regulators, thereby converging on NF-ĪŗB to mitigate MASLD. To improve translational interpretation, animal experimental doses were contextualised using established human-equivalent dose conversion methods, alongside reported dietary sources and estimated achievable intake levels. Although the present work highlights the considerable potential of flavonoids as functional food-derived modulators of the gut microbiota NF-ĪŗB axis in MASLD, their clinical translation remains constrained by limited bioavailability and heterogeneity across experimental models, highlighting the need for standardised dosing strategies, integrated host microbiota analyses, and well-designed human studies to substantiate clinical applicability.
- 4 May 2026
- Published byĀ Springer NatureĀ inĀ Revista Brasileira de Farmacognosia
- Vol.Ā 36 Ā (1) , 48
Therapeutic Potential of Pogostemon in Inflammatory Disorders: A Detailed Review of Phytochemicals and Mechanistic Pathways
- 4 May 2026
- Published byĀ Springer NatureĀ inĀ Revista Brasileira de Farmacognosia
- Vol.Ā 36 Ā (1) , 48
Therapeutic Potential of Pogostemon in Inflammatory Disorders: A Detailed Review of Phytochemicals and Mechanistic Pathways
- 28 April 2026
- Published byĀ Springer NatureĀ inĀ Inflammation Research
- Vol.Ā 75 Ā (1) , 100
Mechanistic insights into natural product-driven modulation of NLRP3-inflammasome signalling in metabolic syndrome
Introduction Metabolic syndrome (MetS) comprises a cluster of interrelated metabolic abnormalities, including obesity, insulin resistance, dyslipidaemia and hypertension, mainly driven by chronic low-grade inflammation. Among innate immune pathways, the Nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has emerged as a critical molecular link between metabolic stress and inflammatory signalling, promoting caspase-1 activation, interleukin (IL)-1β/IL-18 maturation and pyroptosis across metabolically active organs such as adipose tissue, liver and pancreas. Persistent NLRP3 activation, triggered by mitochondrial dysfunction, oxidative stress, ionic imbalance and impaired autophagy, contributes directly to insulin resistance, hepatic steatosis, β-cell dysfunction and cardiometabolic complications, highlighting natural products as promising multi-target modulators capable of attenuating NLRP3-driven metabolic inflammation. Methods The literature search was conducted in PubMed and Scopus to identify recent studies investigating phytochemical-mediated modulation of NLRP3 inflammasome signalling in MetS from 2020 to December 2025. Eligible studies were screened for mechanistic relevance, with particular emphasis on NLRP3-centred pathways. Results and Conclusion The consolidated evidence demonstrates that diverse classes of natural products, including flavonoids, phenolic acids, terpenoids and other bioactive compounds, effectively attenuate NLRP3 activation by suppressing NF-κB-dependent priming, limiting mitochondrial ROS generation, stabilising lysosomal integrity, enhancing AMPK-SIRT signalling and promoting autophagy. Several plant extracts and complex formulations exhibit coordinated metabolic and anti-inflammatory benefits across adipose, hepatic, vascular, neural and renal models of MetS. In addition to summarising their regulatory effects on key inflammatory and metabolic pathways, the review also addresses available toxicity and safety data, thereby providing a more comprehensive perspective on their therapeutic relevance. Overall, this review presents an integrated synthesis of mechanistic and preclinical evidence highlighting natural products as multi-target modulators of NLRP3-mediated metabolic inflammation.
- 28 April 2026
- Published byĀ Springer NatureĀ inĀ Inflammation Research
- Vol.Ā 75 Ā (1) , 100
Mechanistic insights into natural product-driven modulation of NLRP3-inflammasome signalling in metabolic syndrome
Introduction Metabolic syndrome (MetS) comprises a cluster of interrelated metabolic abnormalities, including obesity, insulin resistance, dyslipidaemia and hypertension, mainly driven by chronic low-grade inflammation. Among innate immune pathways, the Nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has emerged as a critical molecular link between metabolic stress and inflammatory signalling, promoting caspase-1 activation, interleukin (IL)-1β/IL-18 maturation and pyroptosis across metabolically active organs such as adipose tissue, liver and pancreas. Persistent NLRP3 activation, triggered by mitochondrial dysfunction, oxidative stress, ionic imbalance and impaired autophagy, contributes directly to insulin resistance, hepatic steatosis, β-cell dysfunction and cardiometabolic complications, highlighting natural products as promising multi-target modulators capable of attenuating NLRP3-driven metabolic inflammation. Methods The literature search was conducted in PubMed and Scopus to identify recent studies investigating phytochemical-mediated modulation of NLRP3 inflammasome signalling in MetS from 2020 to December 2025. Eligible studies were screened for mechanistic relevance, with particular emphasis on NLRP3-centred pathways. Results and Conclusion The consolidated evidence demonstrates that diverse classes of natural products, including flavonoids, phenolic acids, terpenoids and other bioactive compounds, effectively attenuate NLRP3 activation by suppressing NF-κB-dependent priming, limiting mitochondrial ROS generation, stabilising lysosomal integrity, enhancing AMPK-SIRT signalling and promoting autophagy. Several plant extracts and complex formulations exhibit coordinated metabolic and anti-inflammatory benefits across adipose, hepatic, vascular, neural and renal models of MetS. In addition to summarising their regulatory effects on key inflammatory and metabolic pathways, the review also addresses available toxicity and safety data, thereby providing a more comprehensive perspective on their therapeutic relevance. Overall, this review presents an integrated synthesis of mechanistic and preclinical evidence highlighting natural products as multi-target modulators of NLRP3-mediated metabolic inflammation.
- 27 April 2026
- Published byĀ ElsevierĀ inĀ Food Bioscience
- Vol.Ā 80
Indigenous fermented foods of Northeast India: Emerging opportunities in functional foods, microbiota-driven nutrition and safety perspectives
- 27 April 2026
- Published byĀ ElsevierĀ inĀ Food Bioscience
- Vol.Ā 80
Indigenous fermented foods of Northeast India: Emerging opportunities in functional foods, microbiota-driven nutrition and safety perspectives
- 21 March 2026
- Published byĀ ElsevierĀ inĀ Food and Humanity
- Vol.Ā 6
Exploring dietary flavonoid and gut microbiota interactions: Therapeutic insights into metabolic syndrome management
- 21 March 2026
- Published byĀ ElsevierĀ inĀ Food and Humanity
- Vol.Ā 6
Exploring dietary flavonoid and gut microbiota interactions: Therapeutic insights into metabolic syndrome management
- 24 February 2026
- Published byĀ Springer NatureĀ inĀ Molecular Biology Reports
- Vol.Ā 53 Ā (1) , 422
Modulation of mitochondrial biogenesis by flavonoids via SIRT1 signalling in metabolic syndrome: a systematic review
- 24 February 2026
- Published byĀ Springer NatureĀ inĀ Molecular Biology Reports
- Vol.Ā 53 Ā (1) , 422
Modulation of mitochondrial biogenesis by flavonoids via SIRT1 signalling in metabolic syndrome: a systematic review